BioNTech (NASDAQ:BNTX)'s stock had its "hold" rating reissued by analysts at SVB Leerink in a research report issued to clients and investors on Thursday, AnalystRatings.com reports.
BNTX has been the topic of a number of other research reports. Berenberg Bank set a $130.00 price target on shares of BioNTech and gave the company a "buy" rating in a report on Tuesday, April 6th. Wolfe Research assumed coverage on shares of BioNTech in a research note on Monday. They issued an "outperform" rating and a $248.00 price objective on the stock. HC Wainwright reiterated a "hold" rating and issued a $194.00 price objective on shares of BioNTech in a research note on Tuesday. Bryan, Garnier & Co reiterated a "neutral" rating and issued a $206.00 price objective (up previously from $135.00) on shares of BioNTech in a research note on Monday, May 17th. Finally, JPMorgan Chase & Co. set a $104.00 target price on shares of BioNTech and gave the stock a "neutral" rating in a research report on Tuesday, April 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. BioNTech currently has a consensus rating of "Hold" and a consensus target price of $169.83.
Shares of NASDAQ BNTX traded up $21.28 during midday trading on Thursday, reaching $280.89. The company's stock had a trading volume of 230,259 shares, compared to its average volume of 2,197,576. The company has a current ratio of 2.70, a quick ratio of 2.58 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $217.35. BioNTech has a one year low of $54.10 and a one year high of $261.77. The stock has a market capitalization of $67.84 billion, a P/E ratio of 49.20 and a beta of -1.58.
BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Sunday, May 9th. The company reported $4.39 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.09 by $1.30. BioNTech had a net margin of 48.40% and a return on equity of 91.61%. The business had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.40 billion. The business's quarterly revenue was up 7294.9% compared to the same quarter last year. Research analysts anticipate that BioNTech will post 31.59 EPS for the current year.
A number of institutional investors have recently modified their holdings of BNTX. Sterling Investment Advisors Ltd. acquired a new position in shares of BioNTech in the 1st quarter valued at $27,000. John W. Brooker & Co. CPAs acquired a new stake in shares of BioNTech during the 1st quarter worth about $33,000. Captrust Financial Advisors increased its position in shares of BioNTech by 433.3% during the 4th quarter. Captrust Financial Advisors now owns 400 shares of the company's stock worth $33,000 after purchasing an additional 325 shares in the last quarter. Parallel Advisors LLC increased its position in shares of BioNTech by 550.0% during the 1st quarter. Parallel Advisors LLC now owns 325 shares of the company's stock worth $35,000 after purchasing an additional 275 shares in the last quarter. Finally, Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of BioNTech during the 4th quarter worth about $49,000. 12.42% of the stock is owned by hedge funds and other institutional investors.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Further Reading: Secondary Public Offerings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Are all No-Load Funds Equal?7 Stocks That Would Make Great Graduation Gifts
Graduations are often seen as an ending. But they also have the potential to be an exciting new beginning. We may be biased, but we believe an ideal way to launch your graduate into the world is by helping them begin their investing education. And one way to help them do that is by having them invest in what they know.
This current crop of graduates has never lived in a world without things like iPhones, the internet, and they were the generation that likely had smartphones when they were in high school. This is a generation that has embraced and demanded relentless technological innovation. And they have rewarded the companies that have delivered.
Now it’s time to reward them, and maybe yourself as well. In this special presentation, we’ll take a look at seven stocks that would make ideal graduation gifts. Each of these stocks has a lesson(s) for graduates to take throughout their lives and careers.
View the "7 Stocks That Would Make Great Graduation Gifts"